The DOI matches its Crossref record.
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
Abstract
Aerosolized antibiotics are associated with a high treatment burden that can result in non‐adherence to chronic therapy. We evaluated the pharmacokinetics (PK) and safety of tobramycin inhalation powder (TIP), a novel dry‐powder formulation designed to deliver a high payload of tobramycin topically to the lungs for management of chronic Pseudomonas aeruginosa infections. This was a multi‐center, open‐label, sequential‐cohort, single‐dose, dose‐escalation study using the standard 300 mg dose of tobramycin solution for inhalation (TSI) as an active control. Subjects were randomized to TIP or TSI in a 3:1 ratio in each of five cohorts. Measurements included serum and sputum tobramycin concentrations, administration time, serum chemistries, acute change in lung function, and adverse events (AEs). Out of 90 randomized subjects, 86 had data for safety analysis; and 84 had data for PK analysis. Serum tobramycin PK profiles were similar for TIP and TSI. Four capsules of 28 mg TIP (total tobramycin dose 112 mg) produced comparable systemic exposure to 300 mg TSI, in less than one‐third the administration time. The most common AEs associated with TIP were cough (20%) and dysgeusia (17%). TIP allows for faster and more efficient pulmonary delivery of tobramycin than TSI and has a safety profile that supports continued clinical investigation. The increased rate of local respiratory tract irritation noted with TIP is not unexpected with a high‐payload powder formulation. The development of dry powder inhaled antibiotics may represent an important advance in the treatment of chronic lung infections. Pediatr Pulmonol. 2007; 42:307–313. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92
The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy
Mortensen, N. P., Durham, P., & Hickey, A. J. (2014) · Journal of Microencapsulation · doi:10.3109/02652048.2014.932029 · Cited by 52
Metadata
- Authors
- Geller, D. E., Konstan, M. W., Smith, J., Noonberg, S. B., & Conrad, C.
- Venue
- Pediatric Pulmonology
- Publisher
- Wiley
- Published
- 2007-03-12
- Volume
- 42
- Issue
- 4
- Pages
- 307-313
- ISSN
- 1099-0496 (ISSN-L)
- 8755-6863
- OpenAlex
- W2097575804
- Cited by
- 196
- References
- 0
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. https://app.cochat.ai/papers/10.1002/ppul.20594
- The paper
- Geller, D. E., Konstan, M. W., Smith, J., Noonberg, S. B., & Conrad, C. (2007). Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatric Pulmonology. https://doi.org/10.1002/ppul.20594
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.